Mergers & Acquisitions ·
On July 15, 2026, AtaiBeckley Inc. entered into a definitive merger agreement to be acquired by Eli Lilly and Company
ATAIAtaiBeckley Inc.
On July 15, 2026, AtaiBeckley Inc. entered into a definitive merger agreement to be acquired by Eli Lilly and Company. AtaiBeckley shareholders will receive $6.75 per share in cash plus one contingent value right (CVR) per share, which can provide up to an additional $2.50 per share based on clinical and regulatory milestones for BPL-003 and VLS-01. The transaction represents an aggregate upfront equity value of approximately $2.8 billion. The merger is subject to stockholder approval and regulatory clearances, with a termination fee of $104.3 million payable by AtaiBeckley under certain conditions. AtaiBeckley is a clinical-stage biopharmaceutical company developing therapeutics for mental health conditions.